Abstract: The present invention is directed to rapid positioning assistance for a mechanical section of a transcranial magnetic stimulation system. This transcranial magnetic stimulation system comprises a coil section 11 that is in contact with or in the vicinity of the head of the subject, and a mechanical section 30 that supports the coil section 11. The mechanical section 30 includes a plurality of adjustment mechanisms that adjust position of a plurality of movable members, and determines position and attitude of the coil section 11 by adjustment using the plurality of adjustment mechanisms. Receiving means receives desired change for at least one of position and attitude of the coil section 11. Guidance means provides guidance of an adjustment procedure for at least one of the plurality of adjustment mechanisms so as to realize adjustment corresponding to the desired change that has been received.

Abstract: Provided is a configuration capable of executing a detection test for a comfort level including the quality of sleep, which is measurable at home without requiring the measurement of brain waves or electrocardiogram. The respiratory waveform of a subject during sleep is continuously measured and recorded from the respiratory gas flow, etc., and is window-Fourier transformed at each measurement time to generate a frequency spectrum, and a bandwidth including a respiratory frequency is extracted. The index indicating the regularity of the respiratory period of the subject is also calculated at each time point during the sleep, and the time-dependency of this index during the sleep is represented as a graph. A medical device includes a sleep evaluation system equipped with a control means for performing control so that a sleep cycle repeated at a cycle of about 90 minutes is clearly observed if the comfort level including the quality of sleep of the subject is favorable.

Abstract: Provided is a configuration capable of executing a detection test for a comfort level including the quality of sleep, which is measurable at home without requiring the measurement of brain waves or electrocardiogram. The respiratory waveform of a subject during sleep is continuously measured and recorded from the respiratory gas flow, etc., and is window-Fourier transformed at each measurement time to generate a frequency spectrum, and a bandwidth including a respiratory frequency is extracted. The index indicating the regularity of the respiratory period of the subject is also calculated at each time point during the sleep, and the time-dependency of this index during the sleep is represented as a graph. A medical device includes a sleep evaluation system equipped with a control means for performing control so that a sleep cycle repeated at a cycle of about 90 minutes is clearly observed if the comfort level including the quality of sleep of the subject is favorable.

Abstract: A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A- (CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.

Abstract: Provided is an oxygen concentration device which, as an oxygen concentration device having a reduced difference in flow rates of gas which flows through a pressure equalization valve of a pressure equalization path during a purge step and a pressure equalization step, is provided at at least one end side of the pressure equalization valve with a pressure control member having a difference in pressure loss due to the direction of gas flow so that pressure loss of the gas which flows through the pressure equalization path in one direction becomes nearly equal to that of the gas which flows therethrough in the opposite direction.

Abstract: There are provided: 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid, a sodium salt thereof and crystals of these, useful as a therapeutic agent and a prophylactic agent for gout, hyperuricemia and the like, and a method for producing the same.

Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a compressor as a device which can solve a contradictory technical problem of installing an intake sound muffler while downsizing the device under a circumstance that installation of the intake sound muffler is indispensable to reduce intake noise of the compressor, and the compressor comprises: a first lid part provided with a small hole which forms an intake port of the compressor, the lid part constituting a portion of a cylindrical casing of the compressor; a cylindrical part; and a second lid part which forms a small chamber together with the first lid part, wherein the second lid part is provided with a suction nozzle for sucking air into the small chamber.

Abstract: A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained.

Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A training apparatus includes a fixed frame, an training rod, a motor, a rotation information detection sensor, a tilt angle calculation unit, a feedback current detection unit, a position difference calculation unit, and a determination unit. The training rod tilts with at least one degree of freedom. The motor tilts the training rod. The rotation information detection sensor outputs an amount of rotation of the motor. The tilt angle calculation unit calculates a tilt angle. The feedback current detection unit detects a feedback current value. The position difference calculation unit calculates a position difference every time when a first time period elapses. The determination unit determines an error when the position difference generated during the first time period is a first threshold or higher, or when the feedback current value keeps a first current value or higher for a second time period or longer.

Abstract: The present invention is intended to provide a nose drop having high absorption of peptide hormone oxytocin or an acid addition salt thereof, or a derivative thereof through nasal mucosa and little safety concern. The present invention is a pharmaceutical composition for administration to nasal mucosa containing oxytocin or an acid addition salt thereof, or a derivative thereof and a carboxyvinyl polymer, characterized by having an osmotic pressure ratio less than 1.

Abstract: Provided is an expansion-chamber muffler as a downsized sound muffler while keeping a function of noise reduction, comprising: a tube (A) which supplies and evacuates a gas having a noise, wherein the tube (A) in the midway has a cavity with a cross-sectional area larger than that of the tube (A); and at least two or more ports for inflow or outflow of the gas on the lateral side of a tube (B) extending from the expansion-chamber muffler, on the opposite side of the noise source generating the noise.

Abstract: A compact and economical transcranial magnetic stimulation system is provided which allows patient to carry out transcranial magnetic stimulation therapy routinely and repeatedly in, for example, his or her house or a neighborhood primary-care medical facility. The system (1) has a magnetic field generating means for generating a magnetic field to be used for providing magnetic stimulation to a specific part of the patient's head. The magnetic field generating means has a magnetic coil (2) for generating a variable magnetic field, a holder (10) for holding the magnetic coil (2), cameras (150a) and another for recognizing respective reference markings (24) or specific portions of ears of the patient M (tragi (24)), and laser beam oscillators (160a) and another. According to the system, the coil (2) is set in a proper posture with respect to the specific part of the patient by aligning the optical axes of the cameras (150a) and other and the laser beam oscillators (160a) and other with respective tragi (24).

Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a congestive heart failure therapy device that applies a positive pressure within an optimal range depending on the condition of a congestive heart failure (CHF) patient. Provided is a positive pressure therapy device for congestive heart failure patients, comprising: a pressure raising unit configured to raise the pressure of air, or a gas mixture of air and other gases, to a positive pressure; an introducing unit configured to introduce the air or the gas mixture set to a positive pressure into the airways of the patient; and a blood oxygen level measurement unit configured to measure the blood oxygen level of the patient, a blood flow rate measuring unit configured to measure a blood flow rate of the patient, or a cardiac output measuring unit configured to measure a cardiac output of the patient.

Abstract: An oxygen concentration device is provided which, when the number of revolutions of a compressor reaches an upper limit of control, increases an oxygen concentration, and can extend an operating time of the oxygen concentration device, comprising a control means which controls the number of revolutions of the compressor based on a detected value of an oxygen concentration sensor, judges deterioration due to moisture absorption based on the detected value of the oxygen concentration sensor, a detected value of a pressure sensor, and an operating time of an adsorption cylinder and, when criteria for judgment of the deterioration due to moisture absorption are satisfied, makes a purge step time shorter than an initially set time.

Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.